Similar articles

• [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].

  Casacchia M, Barba C, Ruggieri S, Zamponi A, Agnoli A. Casacchia M, et al. Riv Neurol. 1974 Sep-Oct;44(5):303-30. Riv Neurol. 1974. PMID: 4217465 Italian. No abstract available.
• [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].

  Campanella G, Pennetta R. Campanella G, et al. Acta Neurol (Napoli). 1974 May-Jun;29(3):252-63. Acta Neurol (Napoli). 1974. PMID: 4417098 Italian. No abstract available.
• [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].

  Rondot P. Rondot P. Rev Prat. 1974 Mar 11;24(15):1211-2, 1215-6, 1219. Rev Prat. 1974. PMID: 4416964 French. No abstract available.
• Levodopa treatment of Parkinson's syndrome: past and future.

  Pletscher A. Pletscher A. Adv Neurol. 1990;53:469-73. Adv Neurol. 1990. PMID: 2239486 Review. No abstract available.
• Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

  Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Pinder RM, et al. Drugs. 1976;11(5):329-77. doi: 10.2165/00003495-197611050-00001. Drugs. 1976. PMID: 782834 Review. No abstract available.